KR20240004453A - 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체 - Google Patents
변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체 Download PDFInfo
- Publication number
- KR20240004453A KR20240004453A KR1020237038003A KR20237038003A KR20240004453A KR 20240004453 A KR20240004453 A KR 20240004453A KR 1020237038003 A KR1020237038003 A KR 1020237038003A KR 20237038003 A KR20237038003 A KR 20237038003A KR 20240004453 A KR20240004453 A KR 20240004453A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- receptor
- optionally
- cell
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003675 cytokine receptors Human genes 0.000 title claims abstract description 30
- 108010057085 cytokine receptors Proteins 0.000 title claims abstract description 30
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims description 266
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims 94
- 238000000034 method Methods 0.000 claims abstract description 350
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 claims abstract description 276
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims abstract description 275
- 102000005962 receptors Human genes 0.000 claims abstract description 218
- 108020003175 receptors Proteins 0.000 claims abstract description 218
- 108090000695 Cytokines Proteins 0.000 claims abstract description 201
- 102000004127 Cytokines Human genes 0.000 claims abstract description 200
- 230000020411 cell activation Effects 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 555
- 230000027455 binding Effects 0.000 claims description 273
- 210000002865 immune cell Anatomy 0.000 claims description 205
- 108700010039 chimeric receptor Proteins 0.000 claims description 189
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 182
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 119
- 239000000427 antigen Substances 0.000 claims description 106
- 108091007433 antigens Proteins 0.000 claims description 106
- 102000036639 antigens Human genes 0.000 claims description 106
- 108091006024 signal transducing proteins Proteins 0.000 claims description 101
- 102000034285 signal transducing proteins Human genes 0.000 claims description 101
- 230000035772 mutation Effects 0.000 claims description 97
- 102000035025 signaling receptors Human genes 0.000 claims description 95
- 108091005475 signaling receptors Proteins 0.000 claims description 95
- 230000001270 agonistic effect Effects 0.000 claims description 92
- 230000003042 antagnostic effect Effects 0.000 claims description 92
- 239000013604 expression vector Substances 0.000 claims description 86
- 102000008193 Interleukin-2 Receptor beta Subunit Human genes 0.000 claims description 83
- 108010060632 Interleukin-2 Receptor beta Subunit Proteins 0.000 claims description 83
- 108091008874 T cell receptors Proteins 0.000 claims description 81
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 81
- 108091008875 B cell receptors Proteins 0.000 claims description 75
- 102000019034 Chemokines Human genes 0.000 claims description 74
- 108010012236 Chemokines Proteins 0.000 claims description 74
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 72
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 64
- 102100030704 Interleukin-21 Human genes 0.000 claims description 56
- 108010074108 interleukin-21 Proteins 0.000 claims description 56
- 230000011664 signaling Effects 0.000 claims description 51
- 108010002586 Interleukin-7 Proteins 0.000 claims description 48
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims description 46
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 claims description 46
- 239000003153 chemical reaction reagent Substances 0.000 claims description 43
- 229940088597 hormone Drugs 0.000 claims description 43
- 239000005556 hormone Substances 0.000 claims description 43
- 108090000171 Interleukin-18 Proteins 0.000 claims description 39
- 102000003810 Interleukin-18 Human genes 0.000 claims description 39
- 210000000822 natural killer cell Anatomy 0.000 claims description 39
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 38
- 210000000130 stem cell Anatomy 0.000 claims description 37
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims description 36
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 36
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 36
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 36
- 230000004913 activation Effects 0.000 claims description 36
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims description 34
- 102100036509 Erythropoietin receptor Human genes 0.000 claims description 34
- 230000035755 proliferation Effects 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 30
- 210000002540 macrophage Anatomy 0.000 claims description 29
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 29
- 210000004443 dendritic cell Anatomy 0.000 claims description 28
- 210000005260 human cell Anatomy 0.000 claims description 28
- 230000009149 molecular binding Effects 0.000 claims description 28
- 231100000433 cytotoxic Toxicity 0.000 claims description 27
- 230000001472 cytotoxic effect Effects 0.000 claims description 27
- 239000003446 ligand Substances 0.000 claims description 27
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 26
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 26
- 108050003558 Interleukin-17 Proteins 0.000 claims description 26
- 102000013691 Interleukin-17 Human genes 0.000 claims description 26
- 210000004180 plasmocyte Anatomy 0.000 claims description 26
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 25
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 25
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 25
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 25
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 25
- 108010089193 pattern recognition receptors Proteins 0.000 claims description 25
- 102000007863 pattern recognition receptors Human genes 0.000 claims description 25
- 210000004899 c-terminal region Anatomy 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 23
- 230000002688 persistence Effects 0.000 claims description 23
- 101000825399 Homo sapiens SHC-transforming protein 1 Proteins 0.000 claims description 22
- 108090000467 Interferon-beta Proteins 0.000 claims description 22
- 102000003996 Interferon-beta Human genes 0.000 claims description 22
- 108010074328 Interferon-gamma Proteins 0.000 claims description 22
- 102000008070 Interferon-gamma Human genes 0.000 claims description 22
- 102100022340 SHC-transforming protein 1 Human genes 0.000 claims description 22
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 22
- 229960003130 interferon gamma Drugs 0.000 claims description 22
- 229960001388 interferon-beta Drugs 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108010047761 Interferon-alpha Proteins 0.000 claims description 21
- 102000006992 Interferon-alpha Human genes 0.000 claims description 21
- 108700012434 CCL3 Proteins 0.000 claims description 20
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 20
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims description 20
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 20
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 19
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 19
- 108010029697 CD40 Ligand Proteins 0.000 claims description 19
- 102100032937 CD40 ligand Human genes 0.000 claims description 19
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 19
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 19
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 19
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 19
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 19
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims description 19
- 102100035304 Lymphotactin Human genes 0.000 claims description 19
- 102220511953 Replication protein A 70 kDa DNA-binding subunit_R41E_mutation Human genes 0.000 claims description 18
- 230000003013 cytotoxicity Effects 0.000 claims description 18
- 231100000135 cytotoxicity Toxicity 0.000 claims description 18
- 238000013461 design Methods 0.000 claims description 18
- 230000028327 secretion Effects 0.000 claims description 18
- 230000035899 viability Effects 0.000 claims description 18
- 206010063836 Atrioventricular septal defect Diseases 0.000 claims description 17
- 230000036755 cellular response Effects 0.000 claims description 17
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 16
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 102000015696 Interleukins Human genes 0.000 claims description 13
- 108010063738 Interleukins Proteins 0.000 claims description 13
- 238000001211 electron capture detection Methods 0.000 claims description 13
- 101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 claims description 12
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 claims description 12
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 12
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 12
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 12
- 102000006381 STAT1 Transcription Factor Human genes 0.000 claims description 12
- 108010019992 STAT4 Transcription Factor Proteins 0.000 claims description 12
- 102000005886 STAT4 Transcription Factor Human genes 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 12
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 230000004068 intracellular signaling Effects 0.000 claims description 12
- 102000003735 Mesothelin Human genes 0.000 claims description 11
- 108090000015 Mesothelin Proteins 0.000 claims description 11
- 239000000710 homodimer Substances 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 10
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 claims description 10
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 claims description 10
- 101710201820 Insulin receptor substrate 2 Proteins 0.000 claims description 10
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims description 10
- 101710174028 Interferon gamma receptor 1 Proteins 0.000 claims description 10
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 claims description 10
- 102000013968 STAT6 Transcription Factor Human genes 0.000 claims description 10
- 108010011005 STAT6 Transcription Factor Proteins 0.000 claims description 10
- 108010085650 interferon gamma receptor Proteins 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 9
- 239000000833 heterodimer Substances 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 108091007960 PI3Ks Proteins 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 230000004968 inflammatory condition Effects 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 102000004265 STAT2 Transcription Factor Human genes 0.000 claims description 4
- 108010081691 STAT2 Transcription Factor Proteins 0.000 claims description 4
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 4
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 238000012384 transportation and delivery Methods 0.000 claims description 3
- 102220528228 Calcium uptake protein 2, mitochondrial_K40D_mutation Human genes 0.000 claims description 2
- 102220503788 Cytotoxic T-lymphocyte protein 4_L47D_mutation Human genes 0.000 claims description 2
- 102220590441 Epoxide hydrolase 3_S30D_mutation Human genes 0.000 claims description 2
- 102220614306 F-box only protein 4_S12E_mutation Human genes 0.000 claims description 2
- 102220543358 Glucagon-like peptide 1 receptor_L89A_mutation Human genes 0.000 claims description 2
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims description 2
- 102220506655 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1_S79D_mutation Human genes 0.000 claims description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 2
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims description 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 2
- 108010038414 Interleukin-9 Receptors Proteins 0.000 claims description 2
- 102100026244 Interleukin-9 receptor Human genes 0.000 claims description 2
- 102220616164 Secretoglobin family 1D member 2_L86D_mutation Human genes 0.000 claims description 2
- 102220513635 Taste receptor type 2 member 42_L41D_mutation Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 102220363661 c.36C>A Human genes 0.000 claims description 2
- 238000010362 genome editing Methods 0.000 claims description 2
- 238000005734 heterodimerization reaction Methods 0.000 claims description 2
- 102000052622 human IL7 Human genes 0.000 claims description 2
- 102000002467 interleukin receptors Human genes 0.000 claims description 2
- 108010093036 interleukin receptors Proteins 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 102220215574 rs141810266 Human genes 0.000 claims description 2
- 102220075140 rs145870223 Human genes 0.000 claims description 2
- 102220064383 rs150856064 Human genes 0.000 claims description 2
- 102200077465 rs201257588 Human genes 0.000 claims description 2
- 102220076789 rs747976292 Human genes 0.000 claims description 2
- 102220101374 rs878854667 Human genes 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 19
- 102100030699 Interleukin-21 receptor Human genes 0.000 claims 18
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 17
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 8
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 7
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 230000006320 pegylation Effects 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102100026008 Breakpoint cluster region protein Human genes 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000009172 cell transfer therapy Methods 0.000 abstract 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 171
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 37
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 37
- 102100021592 Interleukin-7 Human genes 0.000 description 29
- 229940100994 interleukin-7 Drugs 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 23
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 22
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 22
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 19
- 102000004527 Interleukin-21 Receptors Human genes 0.000 description 18
- 239000000523 sample Substances 0.000 description 17
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 16
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 15
- -1 IL-2 Proteins 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 230000035882 stress Effects 0.000 description 13
- 238000010599 BrdU assay Methods 0.000 description 12
- 241001529936 Murinae Species 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 9
- 108010085238 Actins Proteins 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 230000007781 signaling event Effects 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108010033040 Histones Proteins 0.000 description 8
- 102000006947 Histones Human genes 0.000 description 8
- 241000713666 Lentivirus Species 0.000 description 8
- 239000010432 diamond Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108090000172 Interleukin-15 Proteins 0.000 description 4
- 102000003812 Interleukin-15 Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000010379 pull-down assay Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 3
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 101100365690 Mus musculus Shc1 gene Proteins 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 101150012554 shc gene Proteins 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 201000002025 prostate sarcoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A61K39/4611—
-
- A61K39/4631—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K40/4255—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171933P | 2021-04-07 | 2021-04-07 | |
| US202163172025P | 2021-04-07 | 2021-04-07 | |
| US202163171950P | 2021-04-07 | 2021-04-07 | |
| US202163171980P | 2021-04-07 | 2021-04-07 | |
| US63/172,025 | 2021-04-07 | ||
| US63/171,980 | 2021-04-07 | ||
| US63/171,950 | 2021-04-07 | ||
| US63/171,933 | 2021-04-07 | ||
| PCT/CA2022/050540 WO2022213208A1 (en) | 2021-04-07 | 2022-04-07 | Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240004453A true KR20240004453A (ko) | 2024-01-11 |
Family
ID=83544985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237038003A Pending KR20240004453A (ko) | 2021-04-07 | 2022-04-07 | 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240254182A1 (https=) |
| EP (1) | EP4320168A4 (https=) |
| JP (1) | JP2024515577A (https=) |
| KR (1) | KR20240004453A (https=) |
| AU (1) | AU2022254143A1 (https=) |
| CA (1) | CA3213795A1 (https=) |
| IL (1) | IL307272A (https=) |
| MX (1) | MX2023011880A (https=) |
| WO (1) | WO2022213208A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250057883A1 (en) * | 2021-12-23 | 2025-02-20 | The Trustees Of The University Of Pennsylvania | Controllable stimulation of genetically engineered lymphocytes for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08511000A (ja) * | 1993-04-06 | 1996-11-19 | フレッド ハッチンソン キャンサー リサーチ センター | リンパ球におけるキメラサイトカインレセプター |
| BRPI0918553A2 (pt) * | 2008-09-19 | 2016-03-08 | Maxygen Inc | método para tratar ou previnir neutropenia em um paciente submetido à exposição à radiação, e, uso de uma variante de fator de estimulação de colônia de granulócito. |
| CN117659160A (zh) * | 2015-09-11 | 2024-03-08 | 小利兰·斯坦福大学托管委员会 | 生物相关正交细胞因子/受体对 |
| US20200397821A1 (en) * | 2017-03-03 | 2020-12-24 | Exuma Biotech Corp | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| CN111819192A (zh) * | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| EP4041893A4 (en) * | 2019-10-08 | 2023-08-30 | Provincial Health Services Authority | CHEMERACY CYTOKINE RECEPTORS |
| EP4041760A4 (en) * | 2019-10-08 | 2023-10-11 | Zymeworks BC Inc. | Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same |
-
2022
- 2022-04-07 AU AU2022254143A patent/AU2022254143A1/en not_active Abandoned
- 2022-04-07 US US18/286,045 patent/US20240254182A1/en active Pending
- 2022-04-07 MX MX2023011880A patent/MX2023011880A/es unknown
- 2022-04-07 CA CA3213795A patent/CA3213795A1/en active Pending
- 2022-04-07 EP EP22783744.0A patent/EP4320168A4/en active Pending
- 2022-04-07 KR KR1020237038003A patent/KR20240004453A/ko active Pending
- 2022-04-07 WO PCT/CA2022/050540 patent/WO2022213208A1/en not_active Ceased
- 2022-04-07 IL IL307272A patent/IL307272A/en unknown
- 2022-04-07 JP JP2023562188A patent/JP2024515577A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL307272A (en) | 2023-11-01 |
| WO2022213208A1 (en) | 2022-10-13 |
| MX2023011880A (es) | 2024-01-05 |
| JP2024515577A (ja) | 2024-04-10 |
| EP4320168A1 (en) | 2024-02-14 |
| CA3213795A1 (en) | 2022-10-13 |
| US20240254182A1 (en) | 2024-08-01 |
| EP4320168A4 (en) | 2025-08-20 |
| AU2022254143A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111094345B (zh) | 具有人结构域的抗b细胞成熟抗原嵌合抗原受体 | |
| JP6660297B2 (ja) | 疾患及び障害を処置するためのインターロイキン−１０の使用方法 | |
| JP2025163198A (ja) | キメラサイトカイン受容体 | |
| CN114901684B (zh) | 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子 | |
| WO2020072390A1 (en) | Suicide module compositions and methods | |
| KR20240013750A (ko) | Ras 돌연변이를 표적으로 하는 t 세포 수용체 및 그의 용도 | |
| US20230374454A1 (en) | Human immune cells genomically modified to express orthogonal receptors | |
| JP2021527673A (ja) | キメラ抗原受容体細胞療法と併用するｉｌ−１０剤の組成およびその使用方法 | |
| KR20220131529A (ko) | 변경된 icd stat 신호전달을 갖는 cd122 | |
| WO2024110751A1 (en) | Constitutively active chimeric antigen receptor for treg cell survival and/or persistence | |
| KR20240004453A (ko) | 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체 | |
| WO2024133472A1 (en) | Constitutive cytokine receptors | |
| JP7197538B2 (ja) | メラノーマの処置のための方法および組成物 | |
| KR20200036874A (ko) | 암 치료를 위한 방법 및 조성물 | |
| TW202334398A (zh) | 組成型細胞激素受體 | |
| CN117425679A (zh) | 经修饰的粒细胞集落刺激因子(g-csf)和结合其的嵌合细胞因子受体 | |
| US20210087252A1 (en) | Mutant IDH1 Specific T Cell Receptor | |
| CN121586727A (zh) | 组成型细胞因子受体 | |
| JP2025527729A (ja) | テザリングされたインターロイキン２組み換え受容体及び使用方法 | |
| KR20260033032A (ko) | 합성 시토카인 수용체 | |
| CN117304301A (zh) | 一种结合ssx2抗原的tcr分子及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231103 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250402 Comment text: Request for Examination of Application |